Numinus Wellness has acquired Novamind following Novamind’s receipt of a final order from the BC Supreme Court.
As a result of the acquisition, Numinus now operates 13 wellness clinics, four clinical research facilities and a dedicated psychedelics research lab – positioning the company as a leading integrated mental wellness company providing ketamine- and psychedelic-assisted therapies.
This acquisition significantly grows Numinus’ client service offerings, geographic reach, and revenues.
Numinus has also appointed Dr Reid Robison (MD) as Chief Clinical Officer and Dr Paul Thielking (MD) as Chief Science Officer, who both join the Company from Novamind.
